“We expect to start a Phase III study in the coming months.”

In context

“inst the 6 most prevalent serotypes in North America and Europe. A Phase III trial is underway, and pending positive data and regulatory approval, VLA15 would become the only vaccine available to help prevent the acute severe and long-term health consequences of lime disease global. TAXICOVID is the standard of care COMIRNATY in oral treatment for those at high risk of progressing to severe disease. We believe, however, that there is an opportunity to expand both our therapeutic impact and market position where our next-generation oral antiviral candidate, EBUSATRELVI. In a Phase II study, we have demonstrated a robust antiviral activity at all doses and without the need for returnable boosting. We have addressed the drug-drug interactions and the metallic taste associated with TAXICOVID. We expect to start a Phase III study in the coming months. We are also moving forward with our Phase III program in nonsegmental vitiligo with ritlecitinib, a candidate with a differentiated JAK mechanism developed in-house at Pfizer that has the potential to be an expansion of indications for [indiscernible], which is currently approved in severe alopecia areata. Vitiligo, like alopecia areata , an autoimmune disease with high unmet need. It is the leading cause for skin depigmentation and affects nearly 3 million patients in the U.S. alone. We are also enthusiastic about our 2 first-in-class trispecific antibodies with early data demonstrating excellent 3-in-1 potency. We believe this program has the potential to deliver improved efficacy in atopic dermatitis with an ongoing Phase II study evaluating safety and efficacy. We had a Phase II reado”